October is Liver Cancer Awareness Month | | |
The hepatitis B vaccine is a safe and effective way to prevent chronic liver disease. The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies, children and adults ages 19–59 receive universal vaccination for hepatitis B, and that all adults 18 and older be screened at least once in their lifetime.
Everyone should consider vaccination for lifelong protection. Known as “the first anti-cancer vaccine,” it prevents hepatitis B—the leading cause of liver cancer worldwide. Learn more here.
| |
| Fighting for the hepatitis B birth dose! | | In recent months, new members of the CDC's Advisory Committee on Immunization Practices (ACIP) have taken steps that threaten access to the hepatitis B birth dose in the U.S. and risk undermining public trust in vaccines. At their Sept. 18-19 meeting, ACIP reviewed the long-standing universal hepatitis B birth dose recommendation but chose to delay a vote to remove it. The Committee signaled they will continue considering a shift to a failed risk-based strategy and may also vote to remove federal funding for the vaccine through the Vaccines for Children Program. | | Universal infant vaccine birth dose saves thousands of lives: A response from the Hepatitis B Foundation | | |
In response, the Hepatitis B Foundation, with partners including the American Academy of Pediatrics and the American Association for the Study of Liver Diseases, issued a statement urging ACIP to maintain the universal birth dose. Please read the full statement here.
The Foundation also organized hundreds of public comments, met with Members of Congress, led webinars, created a media toolkit and conducted extensive media outreach to spread our messages and combat misinformation. Through these efforts, we continue to raise national awareness about the critical importance of the hepatitis B birth dose.
| | Liver Cancer Awareness Month Media toolkit | | We’ve created a free, easy-to-use social media toolkit for professionals, community advocates and anyone passionate about raising awareness of liver cancer. You’ll find ready-to-use social media posts that educate about testing, vaccination and liver cancer prevention—making it simple to share vital information and elevate awareness in your community. Click here to access the toolkit and begin posting on your social media platforms today. | | Liver Cancer Connect is a dedicated program of the Hepatitis B Foundation that provides individuals and families with the information and support they need when facing the challenge of primary liver cancer. | | | | Liver Cancer Awareness Month: Featured HCC storytellers | | |
In honor of Liver Cancer Awareness Month, we’re sharing real stories that highlight the importance of awareness, early action and support in the fight against hepatitis and liver cancer. From unexpected diagnoses to powerful recoveries, these voices reveal the power of resilience, advocacy and community.
-
Karen: A teacher and dancer whose unexplained fatigue revealed hepatitis C. After fear and treatment, she found healing and urges others not to ignore the signs.
-
Marjorie: Despite being told her liver cancer was inoperable, she continued teaching, caring for loved ones, and facing treatment with resilience.
-
Paul and Emma: Paul shares how delayed treatment during COVID-19 led to major surgery and a renewed focus on advocacy. Emma offers a caregiver’s perspective, reflecting on hope during recovery.
-
Charles: Shoulder pain and fatigue revealed liver cancer. Thanks to immunotherapy and a transplant, he survived—and emphasizes the power of advocacy and community support.
| | Join us for the virtual Hep B United Mini-Summit | | |
Mark your calendars for Oct. 29–30, 12 to 3 p.m. EDT for this year’s HBU Mini-Summit. Our theme is “Hepatitis B Family Potluck”—a celebration of connection, collaboration and community.
The Summit brings together HBU partners, advocates and community leaders to:
- Exchange successes and challenges,
- Build stronger collaborations and
- Celebrate the diversity and richness of the communities we serve.
We look forward to seeing you there and sharing in this collective space of learning and celebration.
| | | You're invited: The 2025 Bruce Witte Lecture | | Please join us online for the 2025 Bruce Witte Lecture, “HBV: A 60-year journey through history, virology, biomarkers, disease course, and treatment,” presented by Prof. Man-Fung Yuen, J.P., MBBS, MD, PhD, DSc. | | Wednesday, Nov. 12, 2025 | 11 a.m. EST | 📍Virtual (Zoom) | | | | |
Prof. Yuen is Chair Professor at The University of Hong Kong, Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital, and internationally recognized as a leading authority on hepatitis B. With more than 630 publications in top medical journals and over 360 lectures delivered worldwide, his groundbreaking work has shaped the global understanding of hepatitis B, C and liver cancer.
You can learn more about Prof. Yuen here.
| | | Don’t miss this opportunity to hear from one of the foremost experts in the field as he shares insights from decades of research and leadership in HBV prevention, biomarkers, disease progression and treatment. Register to attend online here. | | New blog | Microbiome matters: What your gut says about your liver | | |
There are tiny organisms living in your gut—called the microbiome and they can have a big impact on your liver. Recent research shows that the bacteria and fungi in your digestive system play a major role in keeping your liver healthy and may even affect how hepatitis B progresses.
Key takeaways:
- How the gut and liver are linked through the gut-liver axis,
- What happens when the microbiome is out of balance,
- New research on how gut bacteria change in people with hepatitis B and
- The role of bile acids and bacteria in HBV-related liver disease.
Please read the full blog here.
| | Your gut does much more than help you digest food —it’s deeply connected to your liver and may shape the future of hep B treatments. | | |
New podcast | From neglect to action:
A new era for hepatitis B research in Africa
| | |
Newest Podcast Episode Now Live!
In this episode, we speak with Dr. Claudia Hawkins, Director of the Center for Global Communicable and Emerging Infectious Diseases at Northwestern University. Dr. Hawkins leads the H2NET Initiative, a groundbreaking effort to address critical research gaps in hepatitis B (HBV) and HIV/HBV co-infection across Sub-Saharan Africa.
She shares insights on:
- Challenges of HBV research in resource-limited settings,
- The importance of building local research capacity &
- How H2NET is fostering collaboration to improve health outcomes.
Please listen to the podcast here.
| | |
Dr. Claudia Hawkins
Director, Center for Global Communicable and Emerging Infectious Diseases
Northwestern University
| | New provider education program | | |
Over 300 million people live with viral hepatitis (B, C, D), leading to cirrhosis, liver cancer and transplants. Progress is real—HBV vaccines, curative HCV therapies, WHO guideline updates and Europe’s first HDV therapy—but gaps remain in screening, awareness and timely care.
Expanding testing, prevention and access to treatment—especially for vulnerable communities—is key to eliminating viral hepatitis.
| | | | Hear Prince Okinedo’s powerful message from COLDA 2025 | | |
At the 8th Conference on Liver Disease in Africa (COLDA 2025) in Accra, Ghana, Prince Okinedo (Founder/Team Lead, Hepatitis Advocacy Foundation; member, Community Advisory Board, Hepatitis B Foundation) delivered a powerful talk on the stigma and discrimination faced by people living with hepatitis B.
Please take a moment to view his message.
| | | Upcoming webinar: Scientific, public health and lived experience rationale for expanded and early hepatitis B treatment | | |
Join us for a moderated panel discussion exploring the scientific evidence, public health perspectives and lived experiences supporting the expansion of hepatitis B treatment guidelines.
This webinar is part of the broad dissemination of two recently published papers in The Lancet Gastroenterology & Hepatology on expanded and earlier treatment of hepatitis B. It is co-hosted by the Hepatitis B Foundation and the International Coalition to Eliminate Hepatitis B (ICE-HBV), and will feature authors from each paper.
| | |
Thursday, Oct. 23, at
4 p.m. EDT
| | | | | Read the full press release here. | | TCS New York City 2025 Marathon | | |
We are thrilled to be an Official Charity Partner of the 2025 TCS New York City Marathon!
Join us in supporting our marathon team—Mark Bernstein, Nhi Le, Ian Cohen, Aaron Rak, and Tyler Brenowitz—as they run for hepatitis B awareness and research.
💛Please donate today - please support the Hepatitis B Foundation marathon team.
| | Hear from Shaibu Issa, global hepatitis B advocate, trainer and storyteller. | | New vignette: It was just a routine check-up - meet Maria | | |
Vignettes are stories inspired by real-life events that affect many people living with hepatitis B and D. | | |
In recognition of Liver Cancer Awareness Month, we’re sharing a new patient vignette that highlights a growing but often overlooked risk—metabolic dysfunction-associated steatotic liver disease (MASLD) and how it links to liver cancer.
Maria Lopez had always considered herself healthy. She managed type 2 diabetes and didn’t drink, but a routine checkup revealed abnormal liver tests. Follow-up imaging confirmed MASLD.
Six months later, persistent fatigue led to a new scan, diagnosing early-stage liver cancer. Maria underwent successful treatment and now raises awareness in her community about the connection between metabolic health and liver disease.
| | |
Read the full vignette and learn more about
the link between MASLD, diabetes and liver cancer.
| |
Journal article of the month |
A person-centered hepatitis B approach using the COM-B model to understand barriers and facilitators of hepatitis B testing, management and treatment
Journal of Viral Hepatitis
July 2025
Click here to access the article.
Freeland C, Plunkett Q, Sirapu S, Cohen C
The "capability, opportunity and motivation model," abbreviated as the COM-B model, is a widely used research tool that was used by the authors of this study. In the abstract, they wrote: "Using the COM-B model, a sample of HBV-related direct messages from social media platforms from 2021 to 2023 was collected from individuals directly impacted by hepatitis B. Qualitative analysis was employed for social media messages using a guided codebook and the COM-B model... The themes that emerged corresponded to five COM-B subcomponents and represented barriers relating to psychological capability, physical opportunity, social opportunity, reflective motivation and automatic motivation. Within each of the five subcomponents were subthemes, such as limited knowledge; challenges accessing diagnostics, expert care, clinical trials, and treatment; as well as the social and cultural impacts of stigma, discrimination and quality of life. Future hepatitis B interventions should focus on addressing identified gaps and consider behavioral interventions as methods to address identified barriers. While this study further validated previously identified barriers, it also newly identified motivation among those with hepatitis B to seek out information related to care, management and prolonging life."
| |
- Nov. 12: Bruce Witte Memorial Lecture (see above)
-
April 10 (2026): Hepatitis B Foundation Gala
| |
Learn more about our research and education programs at www.hepb.org
| |
The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public. | | | | | | |